GlassScriptPhysician profile
Peter J Seiler
NPI 1881072254
$5,571.87
in general payments reported to CMS, 2019-2025
28 companies · $944 in 2025
The $944 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $26.16 · 2021: $642 · 2022: $1,109 · 2023: $900 · 2024: $1,536 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,269.05 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $708.93 | 2019-2024 | Aristada, Lybalvi |
| Corium, LLC | $497.37 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $456.14 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $429.95 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $370.31 | 2019-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $341.43 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $327.25 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291.09 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $277.68 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $233.37 | 2021-2024 | Qelbree, Qelbree |
| Almatica Pharma LLC | $228.20 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Abbvie INC. | $184.36 | 2021-2024 | Vraylar |
| Neos Therapeutics, LP | $174.56 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $147.80 | 2025 | Cobenfy |
| Allergan, INC. | $136.18 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $126.27 | 2024-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $118.87 | 2023-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $97.25 | 2022-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $79.47 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $69.67 | 2022-2024 | Trintellix |
| Indivior INC. | $54.08 | 2023-2024 | Perseris |
| Noven Therapeutics, LLC | $54.05 | 2023-2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $52.06 | 2023-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $31.74 | 2022 | |
| Eisai INC. | $28.10 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $22.36 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $18.73 | 2022 | |
| Bausch Health US, LLC | $14.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Seiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.